Advertisement

Topics

Alnis BioSciences, Inc Company Profile

10:18 EST 13th December 2018 | BioPortfolio

Alnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chemotherapeutic payload, the nanoparticles are designed to disintegrate into harmless materials that are subsequently cleared from the patient. Alnis seeks to achieve these goals by combining the latest products and concepts in chemical and biological therapeutics and targeted drug delivery together in a nanoparticle as small as a monoclonal antibody. Alnis' therapeutic particles are nanoscopic hydrogels, or NanoGels. These NanoGels are comprised of biologically active molecules covalently attached to a soluble hydrogel core. The outer surface of the NanoGel is coated with ligands that target diseased tissues. Even if currently marketed drugs are used for all of the components, these NanoGel compositions would in themselves be novel, and because our nanoparticles are comprised of bioactive agents already approved by the FDA, our products may reach market faster than and new chemical entity with lower risk of failure in clinical trials

Research proof-of-concept has been achieved by Alnis and its collaborators with anticancer and antibiotic NanoGels, targeting has demonstrated anti-cancer efficacy both in vitro and in vivo, and diagnostic product candidates have phenotypic-specifically enhanced magnetic resonance images of tumors.. We plan to develop our own proprietary nanoparticle therapeutics and demonstrate their efficacy in humans before partnering with larger companiesAlnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chemotherapeutic payload, the nanoparticles are designed to disintegrate into harmless materials that are subsequently cleared from the patient. Alnis seeks to achieve these goals by combining the latest products and concepts in chemical and biological therapeutics and targeted drug delivery together in a nanoparticle as small as a monoclonal antibody.

Alnis' therapeutic particles are nanoscopic hydrogels, or NanoGels. These NanoGels are comprised of biologically active molecules covalently attached to a soluble hydrogel core. The outer surface of the NanoGel is coated with ligands that target diseased tissues. Even if currently marketed drugs are used for all of the components, these NanoGel compositions would in themselves be novel, and because our nanoparticles are comprised of bioactive agents already approved by the FDA, our products may reach market faster than and new chemical entity with lower risk of failure in clinical trials

Location

626 Bancroft Way #3B
Berkeley
California
94710
United States of America

Contact

Phone: 510-845-1641
Fax: 510-845-1535
Email: alnis@alnis.com


News Articles [594 Associated News Articles listed on BioPortfolio]

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion

Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction....

Strategic partnership forms between Taconic Biosciences and Cyagen Biosciences

A strategic partnership has been formed between Taconic Biosciences and Cyagen Biosciences — both global companies that generate custom genetically engineered rodent models and associated services.

Illumina To Acquire Pacific Biosciences At $8.00/shr

SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN) and Pacific Biosciences (PACB) announced an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in a...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Strategic Advisory Board

Kuros Biosciences appoints Strategic Advisory Board Schlieren (Zurich), Switzerland, September 25, 2018 - Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Boar...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer Schlieren (Zurich), Switzerland, August 23, 2018 Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Long...

FSD Pharma to acquire Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Bios...

Illumina to acquire Pacific Biosciences for $1.2bn

California-based Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems The company’s technology is claimed to offer high accuracy, ultra-long read...

FSD Pharma signs binding LOI to buy Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Bios...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [8 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment fo...

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Companies [373 Associated Companies listed on BioPortfolio]

Alnis BioSciences, Inc

Alnis' ultimate goal is to provide a patient with a therapeutic, a NanoGel, that is able to selectively find and treat diseased tissues with no unwanted effects. Additionally, upon release of the chem...

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

DaVinci Biosciences LLC

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through...

More Information about "Alnis BioSciences, Inc" on BioPortfolio

We have published hundreds of Alnis BioSciences, Inc news stories on BioPortfolio along with dozens of Alnis BioSciences, Inc Clinical Trials and PubMed Articles about Alnis BioSciences, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnis BioSciences, Inc Companies in our database. You can also find out about relevant Alnis BioSciences, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record